HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/gaush-meditech-ltd" target="_blank" data-smartkarma-citation="entities:35250:1" rel="noopener">Gaush Meditech (GMT HK)</a> is a leading total solution provider of ophthalmic medical devices industry.</li>
<li>The irreplaceability of Gaush in the whole industrial chain is actually not high based on its current business model.The proprietary product business may also need to face different policy risks.</li>
<li>Together with other uncertainties such as increasing market competition and medical reform policy in China, we are conservative about Gaush’s outlook at the current stage.  </li>
</ul>



Gaush Meditech (GMT HK) is a leading total solution provider of ophthalmic medical devices industry.
The irreplaceability of Gaush in the whole industrial chain is actually not high based on its current business model.The proprietary product business may also need to face different policy risks.
Together with other uncertainties such as increasing market competition and medical reform policy in China, we are conservative about Gaush’s outlook at the current stage.  


Pre-IPO Gaush Meditech - The "Middlemen" Have Many Challenges

Equity Bottom-Up

Shanghai Haohai Biological Tec / Equity Bottom-Up

Shanghai Haohai Biological Tec (688366 CH)

<ul>
<li>Haohai's development is fuelled by a series of acquisitions, which help Haohai establish the existing diversified businesses, but we haven’t seen any growth point with high certainty.</li>
<li>Compared with Bloomage and Imeik, Haohai has no competitive advantage in the field of medical aesthetics. It’s also difficult for Haohai to make a substantial breakthrough without obvious product advantages.</li>
<li>Although Haohai’s PE/TTM is significantly lower than its peers, due to centralized procurement, Haohai’s valuation could be further lower. Considering the risks, we choose to stay cautious on Haohai.</li>
</ul>


Haohai's development is fuelled by a series of acquisitions, which help Haohai establish the existing diversified businesses, but we haven’t seen any growth point with high certainty.
Compared with Bloomage and Imeik, Haohai has no competitive advantage in the field of medical aesthetics. It’s also difficult for Haohai to make a substantial breakthrough without obvious product advantages.
Although Haohai’s PE/TTM is significantly lower than its peers, due to centralized procurement, Haohai’s valuation could be further lower. Considering the risks, we choose to stay cautious on Haohai.


Shanghai Haohai Biological Technology (688366CH)- Diversified Business Layout Doesn't Secure Outlook

Eyebright Medical Technology / Equity Bottom-Up

<ul>
<li>At the current stage, the price of IOL that won the bidding in centralized procurement was above Eyebright’s ex-factory price, which means that the profits are still guaranteed. </li>
<li>If two core products (IOL &amp; OK lens) are both included in the centralized procurement in the future, Eyebright needs to broaden the product category and find new growth points.</li>
<li>We analyze the valuation from a different angle.We could not say that the current market value of Eyebright is at the bottom, but is more reasonable compared with last June. </li>
</ul>


At the current stage, the price of IOL that won the bidding in centralized procurement was above Eyebright’s ex-factory price, which means that the profits are still guaranteed. 
If two core products (IOL &amp; OK lens) are both included in the centralized procurement in the future, Eyebright needs to broaden the product category and find new growth points.
We analyze the valuation from a different angle.We could not say that the current market value of Eyebright is at the bottom, but is more reasonable compared with last June. 


Eyebright Medical Technology Beijing (688050.CH) - Some Points Worth the Attention

<ul>
<li>In “<em>Investment opportunity in China healthcare industry</em>” we analyzed <a href="https://www.smartkarma.com/entities/ovctek-china-inc" target="_blank" data-smartkarma-citation="entities:29638:1" rel="noopener">Ovctek China Inc (300595 CH)</a>.</li>
<li>However, the stock price has fallen about 43% so far from the record high of RMB109.7/share in June.</li>
<li>Before investors decide to take advantage of this correction, it would be better to look at some potential risks of OVCTEK.</li>
</ul>


In “Investment opportunity in China healthcare industry” we analyzed Ovctek China Inc (300595 CH).
However, the stock price has fallen about 43% so far from the record high of RMB109.7/share in June.
Before investors decide to take advantage of this correction, it would be better to look at some potential risks of OVCTEK.


Ovctek China Inc (300595.CH) - Better See Some Potential Risks Before Making Decisions

<ul>
<li>We analyzed the centralized procurement of IOL and the potential impact on <a href="https://www.smartkarma.com/entities/eyebright-medical-technology-beijing-co-ltd" target="_blank" data-smartkarma-citation="entities:33455:1" rel="noopener">Eyebright Medical Technology Beijing (688050 CH)</a>.</li>
<li>The OK lens and cosmetic contact lenses have strong consumption attribute, indicating "immune" to centralized procurement policy.</li>
<li>We are optimistic about the outlook for Eyebright and there could still be upside potential of its stock price.</li>
</ul>


We analyzed the centralized procurement of IOL and the potential impact on Eyebright Medical Technology Beijing (688050 CH).
The OK lens and cosmetic contact lenses have strong consumption attribute, indicating "immune" to centralized procurement policy.
We are optimistic about the outlook for Eyebright and there could still be upside potential of its stock price.


Eyebright Medical Technology (688050.CH) -The Impact Of Centralized Procurement and Business Outlook

China

Ovctek China Inc. manufactures contact lenses. The Company produces corneal plastic lens, common corneal contact lens, contact lens care solutions, and other products. Ovctek China also produces nursing products, ordinary frame mirrors, and other products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ovctek China (300595 CH)

Pre-IPO Gaush Meditech - The "Middlemen" Have Many Challenges

The irreplaceability of Gaush in the whole industrial chain is not high based on its business model. Gaush's business has to face various policy...

Xinyao (Criss) Wang

Shanghai Haohai Biological Technology (688366CH)- Diversified Business Layout Doesn't Secure Outlook

Haohai builds diversified business via M&A,but none is growth point with high certainty. Its medical aesthetics has no obvious advantage and the...

Xinyao (Criss) Wang

Eyebright Medical Technology Beijing (688050.CH) - Some Points Worth the Attention

For centralized procurement of IOL and OK lens, Eyebright is "safe" in short term but not long term.If see the valuation from a different angle, we...

Xinyao (Criss) Wang

Ovctek China Inc (300595.CH) - Better See Some Potential Risks Before Making Decisions

The insight mainly analyzed OVCTEK in terms of several potential risk points related to its business layout, development strategies,increasing...

Xinyao (Criss) Wang

Eyebright Medical Technology (688050.CH) -The Impact Of Centralized Procurement and Business Outlook

This article mainly analyzed Eyebright Medical Technology in terms of the centralized procurement of IOL and potential impact, as well as the OK...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)